Amicus speeds up its FDA timeline; Salix execs pocket millions after accounting scandal;

@FierceBiotech: J&J stays mum about cash, but biotech buyout is a landmark win for Index fund. Story | Follow @FierceBiotech

@JohnCFierce: Crohn's expert flags blockbuster potential--and frets--of Celgene's mongersen. News | Follow @JohnCFierce

@DamianFierce: Today begins the round of 64 in FierceMadness, a pointless & absurd tournament of drug names. More | Follow @DamianFierce

> Amicus Therapeutics ($FOLD) accelerated its plans to submit its lead drug for regulatory approval following some positive discussions with U.S. and European regulators. The company now plans file migalastat, a treatment for Fabry disease, in the second quarter. More

> Despite a value-destroying accounting scandal, two former Salix Pharmaceuticals ($SLXP) execs are walking away with $46 million thanks to Valeant Pharmaceuticals' ($VRX) pending $11.1 billion acquisition of the company, Bloomberg reports. News

> Daiichi Sankyo is paying $200 million up front to partner up on AstraZeneca ($AZN) and Nektar Therapeutics' ($NKTR) recently approved constipation drug Movantik, promising up to $625 million more depending on sales. Story

Medical Device News

@FierceMedDev: ICYMI: Vivo Capital doubles down to close $750M US-China healthcare fund. Story | Follow @FierceMedDev

@VarunSaxena2: Medtronic's stent for peripheral artery disease wins expanded indication from FDA. Story | Follow @VarunSaxena2

@EmilyWFierce: Changes in public's perceptions of risk contributes to spread of infectious diseases, says NIAID director. More from The Atlantic | Follow @EmilyWFierce

> Boston Scientific subsidiary hit with $50M gender discrimination suit. Report

> Canon BioMedical makes first move with rapid DNA, drug metabolism diagnostic startup. Story

> Medtronic's stent for peripheral artery disease wins expanded indication from FDA. Article

Pharma News

@FiercePharma: Sanofi's Shantha ready to supply 37 million doses of long-delayed pentavalent. FierceVaccines story | Follow @FiercePharma

@EricPFierce: When it comes to Big Pharma revenues, who's the biggest of them all? Special report | Follow @EricPFierce

@CarlyHFierce: Don't forget that there are FOUR regions to vote in today - let's show the oncology drugs some love, shall we? More on FierceMadness | Follow @CarlyHFierce

> Sanofi's diabetes franchise one step closer to U.S. Lyxumia launch. More

> Daiichi shells out $200M-plus to help AstraZeneca launch Movantik. News

> Bristol-Myers chief's last 'paycheck' as CEO is a doozy at $27M. Article

CRO News

> Quintiles taps Google partner Tute Genomics for R&D. Item

> Trial tech outfit Clinical Ink merges with app upstart. News

> Evotec pairs up with Second Genome to gut out some R&D. More

> Catalent shakes up its business with an eye on product launches. Story

> WuXi dives into the CAR-T fray with new plant plans. Article

Vaccines News

> Cancer vaccine maker Aduro files for $86M IPO. Item

> Allergy Therapeutics scores $30M to finish grass allergy vaccine. More

> England to provide GSK MenW vaccine to 3 million teens. News

> GSK to test Ebola jab with booster from Emergent BioSolutions. Report

> More vaccines deals for Pfizer? It wouldn't say no, exec says. Story

Pharma Manufacturing News

> Puerto Rico manufacturing base to grow with AbbVie expansion. More

> Kite Pharma adds manufacturing assets with T-Cell Factory acquisition. Item

> India's Micro Labs recalls drugs made at banned plant. Report

> Wockhardt says FDA impressed by the strides it made at a banned plant. Article

> Lawsuit would force FDA to ban or label wheat gluten as ingredient. Story

Pharma Asia News

> U.S.-based lawsuits pile up for Japan's Olympus in superbug case. Item

> Indonesia drug industry investment lags despite universal insurance program. Article

> Daiichi Sankyo pays $200M to AstraZeneca for Movantik U.S. sales rights. Story

> U.S. FDA softens approach in meetings with Indian regulators. Report

> India's Wockhardt, Granules, suggest recent FDA inspections went well. More

Suggested Articles

Charles River Labs is stumping up $380 million in cash to buy out cell therapy biomaterials producer HemaCare.

Novartis’ fevipiprant has failed another pair of phase 3 clinical trials, prompting the Swiss pharma to halt further development in asthma.

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.